NOMOS Corporation’s Peregrine Radiation Dose Calculation System Approved for Marketing
SEWICKLEY, Pennsylvania-The FDA has granted NOMOS Corporation clearance to market the Peregrine Monte-Carlo-based radiation dose calculation system, licensed from the Lawrence Livermore National Laboratory where it was developed. Peregrine is a computer-based system for quick calculation, in three dimensions, of radiation doses for use with complex intensity-modulated radiotherapy treatment plans. Monte Carlo is a mathematical technique that simulates the trillions of radiation particles that enter the body during treatment. It selects a random sample of these particles and tracks them through a computer model of the radiation-delivery device and the patient’s CT scans to create a detailed map of the dose distribution (see image). NOMOS will initially incorporate Peregrine into its CORVUS inverse treatment planning system, and will then develop a stand-alone version to work with other treatment planning systems.
SEWICKLEY, PennsylvaniaThe FDA has granted NOMOS Corporation clearance to market the Peregrine Monte-Carlo-based radiation dose calculation system, licensed from the Lawrence Livermore National Laboratory where it was developed. Peregrine is a computer-based system for quick calculation, in three dimensions, of radiation doses for use with complex intensity-modulated radiotherapy treatment plans. Monte Carlo is a mathematical technique that simulates the trillions of radiation particles that enter the body during treatment. It selects a random sample of these particles and tracks them through a computer model of the radiation-delivery device and the patients CT scans to create a detailed map of the dose distribution (see image). NOMOS will initially incorporate Peregrine into its CORVUS inverse treatment planning system, and will then develop a stand-alone version to work with other treatment planning systems.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Similar Splenic, Symptom Responses Are Reported With Ruxolitinib Combos in Myelofibrosis With Anemia
June 13th 2025Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.
